SEC Tracker
Get the app
CLDX · XBRL financial data

Celldex Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CLDX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers2year only0231*110*0*00
Cost of goods and services sold—year only———year only———year only——
Research and development3530*32404547*53546375*7368
General and administrative89*991010*11101112*1113
Operating income (loss)(41)(48)*(41)(46)(52)(56)*(63)(64)(74)(87)*(84)(81)
Income tax expense (benefit)—year only———year only———year only——
Net income (loss)—year only(33)(36)(42)(47)*(54)(57)(67)(81)*(79)(74)
Earnings per share, basic USD per share(0.81)—(0.56)(0.54)(0.64)—(0.81)(0.85)(1.01)—(1.18)(0.94)
Earnings per share, diluted USD per share(0.81)—(0.56)(0.54)(0.64)—(0.81)(0.85)(1.01)—(1.18)(0.94)
Weighted average shares, basic millions of shares00*0000*000—6778
Weighted average shares, diluted millions of shares00*0000*000—6778

Balance sheet

CSV

Fiscal quarters (CLDX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents2135115433628172336293647
Marketable securities214389709760720697656607547490416670
Prepaid and other current assets1059822211918211487
Total current assets246432835812779747694648604535459725
Property and equipment, net4444445455710
Right-of-use asset332234433225
Total assets280466869846823792739692648583511782
Accounts payable43341332411015
Accrued liabilities182218192834252840473844
Total current liabilities283126283240323346515161
Lease liability, non-current110122211103
Total liabilities343630323745363750565568
Accumulated deficit(1,354)(1,397)(1,430)(1,466)(1,508)(1,555)(1,609)(1,666)(1,733)(1,814)(1,893)(1,966)
Total stockholders' equity247429839814786747703655598527456715
Total liabilities and equity280466869846823792739692648583511782
Common shares outstanding (cover page) millions of shares475666666666666666677879

Cash flows

CSV

Fiscal quarters (CLDX's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)—year only(33)(36)(42)(47)*(54)(57)(67)(81)*(79)(74)
Stock-based compensation7*7*78*10*10*99*9*9*98*
Depreciation and amortization1*1*11*1*1*11*1*1*11*
Net cash from operating activities(19)*(33)*(41)(29)*(55)*(32)*(54)(44)*(49)*(64)*(66)(57)*
Purchases of property and equipment0*1*00*1*1*01*0*1*23*
Net cash from investing activities12*(171)*(315)(47)*48*24*4350*61*55*72(256)*
Proceeds from issuing common stock—year only4320*0*0*——————
Net cash from financing activities0*217*4364*1*0*00*1*1*0325*
Net change in cash(7)*14*80(72)*(6)*(8)*(11)6*13*(7)*712*

Compare with peers

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Celldex Therapeutics470(57)*78.5M12.5 quarters 10-QJun 30, 2026
Ani Pharmaceuticals36026657*not reported— 10-QJun 30, 2026
Travere Therapeutics12422598*96.0M— 10-QSep 30, 2026
Innoviva57012052*72.2M— 10-QJun 30, 2026
Adaptive Biotechnologies17072(6.4)*159.6M53.8 quarters 10-QJun 30, 2026
Arrowhead Pharmaceuticals5575(177)*141.3M9.0 quarters 10-QJun 30, 2026
Mannkind53109(18)*321.5M6.0 quarters 10-QJun 30, 2026
Schrodinger28859(34)*not reported12.1 quarters 10-QJun 30, 2026
Spyre Therapeutics83not reported(77)*95.0M15.7 quarters 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.